Kirsi Norrbacka

Statistics

Publications

Citations

359

H-Index

Active since

2012

Affiliations

Eli Lilly (United States)(Current)

IQVIA (United Kingdom)

Eli Lilly (Germany)

Ithaka Harbors

Gramercy Research Group (United States)

Kirsi Norrbacka is an author at Eli Lilly (United States) specializing in diabetes mellitus, glucagon-like peptide-1 receptor agonists, and clinical pharmacology.

ORCID

Publications per year

2012–2021

Publications

GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data

Victoria Divino, Kristina S. Boye, Jérémie Lebrec et al. · Diabetes Therapy · 2019 · 41 citations · Full text

Medicine, Endocrinology, Pharmacology +17

GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries

Victoria Divino, Mitch DeKoven, Farhad Khan et al. · Diabetes Therapy · 2017 · 37 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus in Italy: A Retrospective Cohort Study

Marco Orsini Federici, Janette P. McQuillan, Giovanni Biricolti et al. · Diabetes Therapy · 2018 · 37 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Differences in the use of guideline-recommended therapies among 14 European countries in patients with acute coronary syndromes undergoing PCI

Uwe Zeymer, Stefan James, Guy Berkenboom et al. · European Journal of Preventive Cardiology · 2012 · 29 citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m<sup>2</sup>in Spain

Tiago A. H. Fonseca, John Clegg, G Caputo et al. · Journal of Medical Economics · 2013 · 27 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17

1–5 of 16